We conducted a 10-yr prospective study of peak bone mass and its change in 604 women, aged 24 -44 yr at study initiation, and related changes in bone mineral density (BMD) and osteocalcin (OCN) concentrations to estrogen receptor (ER) ␣ gene polymorphisms in 442 of these women.
F AILURE TO ACCRUE adequate peak bone mass and loss of peak bone mass, particularly during the later perimenopause, can lead to lower bone mineral density (BMD) immediately after menopause and into subsequent older age (1) . Although evidence suggests that the bone loss process can occur before menopause, few risk factors for low premenopausal BMD and for greater pre-and perimenopausal bone loss have been delineated (2) (3) (4) (5) . Genetic, anthropometric, reproductive, and lifestyle-related factors may contribute to the variation in either peak BMD or its rate of loss. For example, among premenopausal women, body weight has been consistently and positively associated with BMD (5-7). Selective reproductive characteristics, such as irregular menses and amenorrhea, have been consistently associated with lower BMD, lactation has been associated with transient bone loss, and age at menarche has shown inconsistent association with BMD or long-term bone change (8 -11) .
BMD is highly heritable, as demonstrated by comparisons of intrapair differences in BMD between monozygotic and dizygotic adult twin pairs, where heritability estimates of BMD range from 45-84%, depending on the skeletal site being examined (12) (13) (14) . Sowers et al. (14) reported that approximately 50% of variation in femoral neck (FN) peak BMD was potentially genetic, based on data from a modified family study. The extensive list of candidate genes for study as determinants of BMD includes the nuclear estrogen receptor (ER␤ or ER␣), including two polymorphisms in the first intron that can be defined by the restriction enzymes PvuII or XbaI (15, 16) . This candidate gene has been widely studied based on the recognition of the importance of estrogen on bone as demonstrated by change in bone mass with the menopausal transition, treatments involving estrogen replacement (17) , and the decreased mineralization observed in the ER␣ knockout mouse model (18) . Despite numerous studies, the role of ER polymorphisms remains unclear, although a recent metaanalysis suggests a potential role for groups defined by the XbaI genotypes compared with groups defined by the PvuII genotypes (15) .
To date, most human studies of genetic associations with BMD have been cross-sectional, in which genotypes have been related to level of BMD or to fractures, but few studies have related genotypes to BMD change over time. Likewise, there are few studies that have included bone turnover markers, such as osteocalcin (OCN) or N-telopeptides, which would give a more proximal measure of the association of genotype with BMD and its relationship to bone remodeling activity.
We completed a large, community-based, 10-yr prospective cohort study of bone and its change in pre-to early postmenopausal women, and we related BMD change and OCN serum levels to selected polymorphisms of the ER␣ gene. We determined the association between ER␣ genotypes and the 10-yr change in BMD and 10-yr OCN patterns in women approaching and transitioning to menopause. We also determined whether the association of change in serum OCN concentrations with FN and spine BMD change over time was different according to genotype.
Subjects and Methods
This study is a component of the longitudinal Michigan Bone Health Study, a study that has been described previously (4) . This populationbased study of women, aged 24 -44 yr in 1992 when BMD measurement with dual energy x-ray densitometry was initiated, recruited the women from two lists. The first list identified the female children in families from the Tecumseh Community Health Study, a prospective cohort study of families that had been established in 1959. There were 539 adult daughters (Ͼ80% participation) of these families still living in the community who were successfully recruited to the Michigan Bone Health Study using letters, telephone calls, and in-person visits. A second list was used to identify and recruit those women who were current Tecumseh community residents but whose families had not lived in Tecumseh when the Tecumseh Community Health Study was undertaken in 1959 -1969. There were 135 age-eligible female Tecumseh residents who were identified from Kohl's Directory, a list that included age, name, address, and telephone number, and of these women, 121 (87%) were enrolled. The total cohort, identified from the combined lists, included 660 age-eligible Caucasian women.
Data for these analyses were collected nine times in the 10-yr period (1992/1993 to 2002 and excluding 1996/1997). Women may not have been evaluated in any given year because they declined (Ͻ14% in any given year), moved from the area (1-5% in any given year), reported significant health impairments (1-2% in any given year), or died (n ϭ 6). An annual measurement was deferred to the following year if the enrollee was pregnant (1-3% in any given year). More than 64% of the study population was assessed at all nine evaluations, and almost 80% of the population had at least seven of the nine evaluations. Genotyping was completed in 442 of these enrollees. Written informed consent was obtained annually from all participants, and approval for the conduct of the study was obtained from the University of Michigan Institutional Review Board.
BMD and OCN measures
BMD was measured at the lumbar spine (LS; L [2] [3] [4] ) and the FN with dual-energy x-ray absorptiometry (DPX-L; Lunar Corp., Madison, WI) and the same software (version 1.3y) at all time points. Coefficients of variation for the dual-energy x-ray absorptiometry measurements of the LS and FN were less than 1.0% in a study of repeated measures conducted at the study inception in 20 women. The densitometer was calibrated daily and a spine phantom was measured weekly to assure that drift did not occur in BMD measures or that periodic maintenance did not result in change that was artifact.
At each annual examination, blood was drawn on d 3-7 of the follicular phase of the menstrual cycle and after women had been fasting for 8 h. For those women without menstrual bleeding, blood was drawn fasting on the anniversary date of their first annual examination. Serum was stored in an ultralow freezer at Ϫ80 C and had no thaws and refreezes before assay for OCN. OCN, a bone matrix protein released into circulation by osteoblasts during bone formation and during the enzymatic degradation of the bone matrix, was selected as a measure of bone turnover (19) . OCN concentrations were measured in batch using a RIA (Incstar, Stillwater, MN) with a combined inter-and intraassay variation of less than 10% and modeled as a time-varying covariate. We used logistic regression to generate a model for imputation and address OCN measurements that were below assay detection limits (0.05 nmol/ liter). Based on the property of homogeneity, we replaced a random number for the data censored due to underdetection. The number of OCN values that were below detection [42 (7.5%) in 1992; 55 (9.7%) in 1993; 32 (7.4%) in 1994; 23 (4.6%) in 1995; and three or fewer (Ͻ0.6%) per year in 1998 and later] declined over time as the population increased with age.
Anthropometry
The height (cm) and weight (kg) of participants, wearing light clothing and stockings without shoes, were measured annually with a stadiometer and a calibrated balance-beam scale, respectively. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters (kg/m 2 ) and was modeled as a time-varying covariate.
Reproductive history
Interviews were used to assess menstrual status and exogenous hormone use at each examination. A multilevel variable for menstrual status was based on the frequency of menstrual bleeds per year, hormone use, and having gynecologic surgery or treatment with chemotherapy. There was medical record confirmation of 75% of reported unilateral oophorectomies, 79% of reported hysterectomies, and 90% of reported bilateral oophorectomies. Failure to confirm surgeries and chemotherapy was, in large measure, due to the consolidation of health care providers and systems in the area and misplacement of archival records. Women were classified as postmenopausal if they reported the absence of a menstrual bleed for a 12-month period or a history of bilateral oophorectomy.
Lifestyle
At each interview, current physical activity level was measured with the self-administered Stanford Five-City instrument (20) , where participants recalled the number of minutes of physical activity during the previous January and the previous July. Intensity of physical activity (summed to encompass the winter and summer data) was expressed in METS per week, with one MET defined as the energy consumed per minute of sitting at rest, and was modeled as a time-varying covariate. Dietary information was collected in the first four annual examinations with the Block-National Cancer Institute Health, History, and Habits Questionnaire (21) and DIETSYS software (HHHQ-DIETSYS Analysis software, version 3.0; National Cancer Institute, Bethesda, MD). Depending on the year, data from 55-73 women were excluded from the dietary analysis because their reports included too few foods or too few calories to meet the data checking criteria. Women reported their annual alcohol beverage consumption, and the data were expressed as ounces per month. Nutrients, dietary energy, and alcohol consumption were modeled as time-varying covariates. At each interview, women classified themselves as a current smoker, ex-smoker, or never smoker, and a summary variable was updated when a woman reported a change in smoking status.
Family history and genotyping
Enrollees reported whether any maternal or paternal first-degree relative had an osteoporosis diagnosis, dowager's hump, or weak bones (a term used to describe osteoporosis among health care providers around the community). Family history of osteoporosis was defined as any positive report through 1998/1999 and was modeled as a summary variable.
DNA was extracted and amplified from 2-3 ml of whole blood, and genotyping was completed for 442 women. Red blood cells were lysed at 4 C in cell lysis buffer (0.32 m sucrose; 10 mm Tris-HCl, pH 8.0; 5 mm MgCl 2 ; and 1% Triton X-100). After three cycles of lysis, the final lymphocyte pellet was resuspended in 10 mm Tris-HCl (pH 8.0), 10 mm NaCl, 10 mm EDTA, and proteinase K (final concentration, 1 mg/ml). Samples were incubated at 55 C overnight with periodic mixing to disperse the pellet; an aliquot of 1-3 l (50 -300 ng of DNA) was used for each PCR.
Primers designed to amplify intragenic polymorphic PvuII and XbaI sites were derived from Kobayashi et al. (22) . Amplification conditions were as follows: 94 C (3 min), followed by 35 cycles at 94 C (1 min), 58 C or 60 C (45 sec), and 72 C (1.5 min). Amplifications were carried out in a 480 Perkin-Elmer thermocycler (Wellesley, MA). After each PCR, an aliquot of amplified material was cleaved with the appropriate restriction endonuclease, according to manufacturers' specifications (New England Biolabs, Beverly, MA). The presence (ϩ) or absence (Ϫ) of the enzyme recognition site was identified by ethidium bromide staining of fragments separated in 6% polyacrylamide. Genotypes were independently verified by two individuals.
Statistical analysis
The relationship between time and 10-yr change was assessed for FN BMD, LS BMD, and OCN. Univariate statistics were computed for con-tinuous variables, and frequencies were determined for categorical variables. Variables with highly skewed distributions were transformed using a logarithmic function or categorized.
The linear and quadratic relationships with time were evaluated for each outcome variable alone and after inclusion of each genotype. LS BMD and OCN had a constant (linear) rate of change. The rate of change in FN BMD was identified as having a curvilinear (quadratic) component. Accordingly, all models for FN BMD included a quadratic time component, whereas the time component for OCN and LS was modeled as a linear function.
Repeated measures models were used to test for an association between phenotypic characteristics and genotypes at each genetic locus. Genotype variables were tested for their associations with bone loss or OCN change and were modeled either as main effects or as interactions with time, with the SAS Procedure MIXED (SAS Institute, Inc., Cary, NC) in the following form:
where BMD ij is the value of BMD for the i th person at time j, timeЈ ij is the j th time point for person i [adjusted for mean time, i.e. timeЈ ij ϭ (time ij Ϫ mean time)], x i is the value of the genotype for the i th person, b i is a random intercept term to account for correlated errors among repeated measures on the same woman, and ⑀ ij is an error term. The ␤ 1 (timeЈ) coefficient provides an estimate of the average annual rate of bone loss for premenopausal (the referent group) women, and the ␤ 2 (timeЈ 2 ) demonstrates how the annual rate of bone loss changes over time. The ␤ 3 genotype coefficient provides an estimate for the difference in BMD or OCN associated with a unit change in the specific genotype. A significant ␤ 4 (risk factor) coefficient is interpreted as a difference in baseline BMD according to level of the risk factor only if there is a corresponding timeЈ by risk factor interaction. The ␤ 4 coefficient can be interpreted as the association between the genotype and BMD at any time over the 10-yr study. The ␤ 4 coefficient (timeЈ by genotype) and the ␤ 5 coefficients (timeЈ 2 by genotype) estimate the BMD or OCN change according to genotype level over time (23, 24) .
Covariates available for incorporation into the models included baseline smoking, alcohol consumption, usual daily dietary intake of calories and calcium, thiazide medication use, and physical activity, but these were not included in final models because they were not statistically significant. Covariates retained in the model included baseline BMD (or baseline OCN, as appropriate), BMI, and a status variable to describe menstrual status and hormone use. Gene-by-environment interactions were not estimated. Family history of osteoporosis or osteoporotic fracture was evaluated for its potential contribution as a main effect and in interaction with OCN or genotype. Analyses were undertaken using SAS 8.0 (SAS Proprietary Software, Release 8.0; SAS Institute).
Results
Baseline characteristics of the study population are shown in Table 1 . The average age of the study population at the inception of the 10-yr study period was 37 yr, with a span from 24 -44 yr. At baseline, women were premenopausal, with the exception of 34 women who had a bilateral oophorectomy and three women with premature menopause, and 21 of these women were using hormone replacement therapy (HRT). In 2002, when the age range was 34 -54 yr, 69% of women were still classified as premenopausal. The mean (Ϯ sd) usual daily dietary calcium intake was 758 (Ϯ 455) mg, whereas the usual median dietary calcium intake was 667 mg.
The amount and direction of BMD change over the 10-yr period is shown in Table 2 as a ␤ coefficient Ϯ se. Over the 10-yr period, there was a modest and linear 1.5% BMD loss at the LS (P Ͻ 0.0001) and a 2.2% loss of FN BMD that was mildly curvilinear. As shown in Fig. 1 , as OCN concentrations increased over time, there was BMD decline at both the FN and LS. The OCN concentrations increased significantly and linearly by approximately 10% over the 10-yr period, as estimated with a regression coefficient (P Ͻ 0.003).
A family history of osteoporosis, reported by 38% of women, had slightly greater OCN turnover over time and lower BMD, but the difference in BMD change was not significant when compared with women with no family history of osteoporosis.
The frequency of each of the genotypes is shown in Table  1 . There is no evidence of deviation from Hardy-Weinberg equilibrium for the selected polymorphisms (P Ͼ 0.05).
LS loss
As shown with regression coefficients in Table 3 , there was linear decline in LS BMD over time and a greater change in postmenopausal women compared with premenopausal women. A statistically significant interaction term was used to identify that the rate of bone loss varied according to genotype. There was less change in LS BMD in those women who were PvuII (Ϫ/Ϫ) homozygotes compared with women who were PvuII (ϩ/ϩ) homozygotes (P ϭ 0.0007). Likewise, there was less change in LS BMD in those women who were XbaI (Ϫ/Ϫ) homozygotes compared with women who were XbaI (ϩ/ϩ) homozygotes (P Ͻ 0.02).
FN
As shown with the regression coefficients in Table 4 , the change in FN over the 10-yr period was mildly curvilinear downward and more evident in those women who because postmenopausal compared with those women who remained premenopausal. Lower OCN concentrations and their change over time were linearly associated with change in FN BMD.
Both ER genotypes were associated with level of BMD, with greater levels being observed for women who were PvuII and XbaI (Ϫ/Ϫ) homozygotes. As shown in Fig. 2 , there was a significant OCN by genotype interaction, suggesting that the amount of FN BMD change per unit of OCN change depended upon the genotype group, particularly the XbaI genotype groups. As an example, there is a significant difference (Ϫ0.029 g/cm 2 ; P ϭ 0.05) between the unit change of FN BMD of XbaI (Ϫ/Ϫ) homozygotes. However, when OCN levels increased over time, the FN BMD decreased more rapidly in the Ϫ/Ϫ group and somewhat faster in the ϩ/Ϫ group than in the ϩ/ϩ group (P Ͻ 0.05). 
Discussion
Examining the potential genetic contribution to peak bone mass accretion and maintenance is important for two reasons. First, there are relatively few factors that explain peak BMD variation. Second, there is little information about whether peak bone mass is similarly retained among all women with diverse genotypes until the menopausal transition. Further, a genetic contribution to BMD and its change may be more readily identified in premenopausal women before menopause and aging confound the effect of genotype on BMD. We found that the linear 10-yr rate of change in LS was different among groups of women characterized by the presence or absence of variants of the ER as defined by the restriction enzymes PvuII and XbaI. The FN BMD loss was also different among the genotype groups, but the rate of change was more strongly tied to the change in OCN over time. To our knowledge, this is the first time that the change in BMD or OCN according to ER genotype has been reported.
The ER␣ gene maps to chromosome 6q25, and the polymorphisms defined by the two restriction enzymes PvuII and XbaI are in close proximity (ϳ45 bp apart) in the first intron (25) . We found that women with the XbaI (Ϫ/Ϫ) genotype had higher FN BMD and less change in LS over time. These findings are consistent with and extend the summary findings from the metaanalysis of the associations of ER␣ with BMD and fracture risk (16) .
We found that women with the PvuII (Ϫ/Ϫ) genotype had less LS BMD change over time as well as higher FN BMD. This is inconsistent with the metaanalysis that reported no association of the PvuII genotypes with BMD or fractures (16) . However, we observed that the higher FN BMD was dependent upon the rate of bone turnover as estimated by OCN concentrations and their change over time. We found that increasingly higher OCN concentrations, a bone matrix protein released into circulation by osteoblasts during bone formation and during the enzymatic degradation of the bone matrix (19) , were greater in women with greater bone loss, which was consistent with other studies (26) . However, the women that were PvuII (Ϫ/Ϫ) homozygotes did not have the same BMD turnover for the increase in OCN units. The metaanalysis did not address such interactions, probably because they are infrequently reported in the literature. Further, our study does not identify the mechanism of this interaction because, as identified by Lindberg et al. (27) , this could include gene by gene interactions with growth factors and inflammatory cytokines.
Our study reports statistically significant associations of the ER genotypes with BMD and its change, but it is important to consider the relative impact of these genotypes with respect to other covariates. As seen in each of the tables, the relative importance of these genotypes was minimal, which is not surprising considering the polygenic and multifactorial nature of BMD (28) . Two factors, baseline BMI and change in menstrual status, were stronger predictors of both level and 10-yr rate of change in BMD than the ER genotypes, and these predictors have consistently and repeatedly been reported (3, 5, 6, 28 -30) .
We observed progressively greater bone change in postmenopausal women compared with premenopausal women, even when these women were using HRT. The effect of estrogen is believed to be mediated by the nuclear ER␣ and/or ER␤, although the direct mechanisms of estrogen on bone are not completely understood (17) . However, because most women had not actually experienced an observable transition to postmenopause, we did not test whether the rate of BMD loss among postmenopausal women was different in groups defined by the ER genotypes.
Women with greater BMI at baseline had a positive, not negative, change in BMD. The contribution of BMI could reflect at least two mechanisms. First, women with greater BMI can have the experience of increased bone loading, generating an environment of greater BMD (31) . Likewise, adipose tissue is increasingly acknowledged as an endocrine organ, and with greater BMI, a greater number of adipocytes increases with the potential for aromatization of androstenedione to estrone (32) . Although estrone is less biologically active than circulating estradiol, the most biologically active estrogen in premenopausal women, adipose tissue could become an increasingly important estrogen hormone source in the postmenopausal period. Although we identified no ER␣ genotype interaction with BMI, the size of the adipose pool in relation to ER markers may become more important as more study enrollees become postmenopausal. Although this study reported an association that appears related to the differential response of BMD with OCN, it does not establish an actual functional role for the genotypes. If the ER genotypes are important in this relationship, it is possible that the reported genotypes are linked to other causative sequence variants. For that reason, one recent investigation reported the association of eight ER␣ variants, including the polymorphisms reported here, to HRT therapy and highdensity lipoprotein cholesterol in women with coronary disease (33), yet a functional role was not resolved in that report and remains uncertain.
This study has a number of strengths and limitations. The longitudinal methods used in this study included the ability to reclassify an exposure that may change with time (such as OCN concentration) and to accumulate events (such as reproductive events) over time (23, 24) . The use of these methods may have diminished any misclassification bias and increased the power necessary to detect associations with BMD change over time. This study has sustained high participation over time, suggesting that findings are not likely to be biased because of loss to follow-up. Indeed the lowest participation occurred in mid-study, and participation actually increased over time. However, the size of the study population coupled with the distribution of the genotypes limited the power to detect some associations. Because almost two thirds of the women were still premenopausal at the end of the study period, potentially important interactions between the genotypes and the experience of the menopausal transition could not be evaluated.
In summary, there was a linear loss of LS BMD and curvilinear loss of FN BMD over a 10-yr period in a population- based sample of women aged 24 -44 yr at study inception. Those women homozygous for the ER␣ gene variant without an XbaI restriction site had higher FN BMD and less change in LS over time. Further, women homozygous for the ER␣ gene variant without a PvuII restriction site had less LS BMD change over time as well as higher FN BMD. However, this higher FN BMD was dependent upon the rate of bone turnover as approximated by OCN concentrations and their change over time. Although these genotype associations were statistically significant, their magnitude was overshadowed by two other factors. Women with higher baseline BMI had less bone loss, and women who became postmenopausal within the 10-yr period had greater loss even when using HRT.
